The EPO published patent application EP4308549A1 for Jiangsu Hengrui Pharmaceuticals covering nitrogen-containing heterocyclic ketone compounds (IPC classifications C07D 251/46, C07D 401/04, C07D 401/12, C07D 405/04, C07D 405/12, C07D 405/14, C07D 413/14, C07D 471/04) and their medicinal uses. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). Therapeutic indications target cardiovascular conditions under A61P 9/04 and 9/10.

This is a granted patent publication rather than a regulatory requirement. Pharmaceutical companies developing competing heterocyclic ketone compounds for similar therapeutic applications should review this patent for freedom-to-operate implications. The patent provides Jiangsu Hengrui with exclusionary rights in designated European states. No compliance deadlines or penalties apply to this instrument type.